DalsnaFinance › IPOs › Iambic Therapeutics › IPO
Iambic Therapeutics, Inc. completed its initial public offering on Nasdaq on October 13, 2026, pricing at $16.00 a share.
| Ticker | IAM |
|---|---|
| Exchange | Nasdaq |
| Status | Completed |
| Listing date | October 13, 2026 |
| Offering price | $16.00 |
| Shares offered | 9,375,000 |
| Total raised | $150M |
| Sector | Biological Products, (No Diagnostic Substances) |
Iambic Therapeutics, Inc. listed on Nasdaq on 2026-10-13.
Ingested from SEC EDGAR (424B4, 8-A12B), CIK 1997038.
Iambic Therapeutics, Inc. sold 9,375,000 shares at $16.00 each on Nasdaq. Multiplied out, that is $150 million in gross proceeds, the figure before underwriting discounts and offering expenses, and it agrees with the $150 million total recorded for the deal.
Measured by money raised, Iambic Therapeutics, Inc. was tied for the 264th largest (level with 34 other deals) of 468 completed IPOs with a recorded deal size that this site tracks since October 20, 2024. The median deal in the same window raised $200 million.
Among the 8 listings on Nasdaq alone, it is the 6th largest.
Its $16.00 offer price was tied for the 108th highest (level with 14 other listings) of the 484 listings in the window with a recorded price. A share price on its own says nothing about a company's value; it depends on how many shares exist.
Iambic Therapeutics, Inc. — quote, profile and latest news →
Source: SEC EDGAR filings for Iambic Therapeutics, Inc.. This page is general information, not investment advice.